Manager – Business Development (API & CDMO) at Ami Lifesciences Pvt. Limited (2025-11 – Present)
Territory: USA & EU. Business Revenue Managed: $10.3M
- Managed top 10 global enterprise Generics Pharma account; launched 5 new products; drove 20% QoQ revenue growth to secure a $6.8M FY27 projection.
- Founded CDMO business line; onboarded 5 new accounts across USA, EU & Japan; scaled baseline revenue to $3.2M with a $7.4M FY27 target.
- Secured a 10+ year exclusive long-term supply agreement (LTSA) with a major Japanese innovator for pharmaceutical intermediates.
- Generated 40+ qualified B2B leads globally; expanded the sales enquiry funnel by ~40% YoY to accelerate new customer acquisition.
- Led 3+ member cross-functional team (Business Ops, Pre-sales, Strategy): streamlined execution and optimized the Go-To-Market roadmap.
Deputy Manager – Business Development & Marketing (API & CDMO) at Jubilant Ingrevia Ltd. (2023-09 – 2025-11)
Territory: USA & EU. Business Revenue Managed: $9.1M
- Onboarded 3 new big Pharma account; closed a $2M project; drove ~20% YoY regional revenue uplift.
- Owned full-cycle sales for $9M pipeline via Salesforce & SAP-CRM: improved win rate with stage gating.
- Generated 50+ qualified leads from tradeshows like -CPHI/DCAT/Chemspec/JPM Bio partnering, email, and LinkedIn; +35% win rate conversion in RFP & RFQ.
- Partnered with R&D/QA/Production on projects to de-risk tech transfer (−25% issues).
- Founded Semiconductor Chemicals Division; scaled from zero to $0.75M global sales in 1.5 years across USA, EU & Japan.
- Launched 10+ semiconductor chemical products in 24 months, opening a new revenue stream.
Senior Executive – Business Development & Launch Management (FDF) at Viatris (Mylan Laboratories) (2023-03 – 2023-07)
Territory: EU & ROW. Business Revenue Managed: $12M
- Negotiated a 3-year, $12M supply agreement for injectables & biosimilars; exceeded quarterly target by 10%.
- Closed $1M in biotech deals in 4 months; expanded footprint across key ROW markets.
- Tightened S&OP cadence with manufacturing; stock-outs reduced by 12% and forecast adherence improved.
- Drove EU market entry for 2 biosimilar products, accelerated access via partner registrations.
- Mapped 5 strategic biotech prospects and multi-threaded decision makers: improved pipeline quality by 14%.
Executive – Business Development & Portfolio (API) at Teva Pharmaceuticals (2021-11 – 2022-12)
Territory: USA. Business Revenue Managed: $8.5M
- Acquired 4 enterprise pharma accounts; delivered $7.3M integrated API deals; +25% retention uplift.
- Built pricing frameworks compliant with ICH Q7/Q10; +10% margin expansion.
- Rolled out executive dashboards (Salesforce/Power BI) for pipeline health and forecast accuracy.
- Segmented target accounts by potential; +15% conversion on high-value pursuits.
Executive – Portfolio Management (CDMO & CRO) at Solara Active Pharmaceutical Ltd. (2019-05 – 2021-11)
Territory: USA. Business Revenue Managed: $12.1M
- Managed 10+ CDMO programs end-to-end; achieved 93% on-time delivery within budget/resource.
- Built pricing frameworks for both FFS & FTE projects; +10% EBITDA margin improvement.
- Established risk registers and mitigation playbooks; project delays cut by 20%.
- Built CAPEX/OPEX tracking for PMO; budget adherence improved by 20%.
- Coordinated global cross-functional teams; communication efficiency up 30%.
